DiaMedica Therapeutics Inc.
NASDAQ:DMACBiotechnology
-$0.01 today
- Market cap
- $463.49M
- Beta
- 1.00
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.65
Volume 0.21M
Average 0.19M
DMAC Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
DiaMedica Therapeutics Inc.NASDAQ: DMAC
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin grows, but more slowly than its trailing trend
Q1 FY2026 selling, general & admin of $2.5M rose 0.3% year over year, behind the +21.7% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +28.3% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $2.5M-0.8% QoQ
- Last fiscal yearDec 2025
- $9.78M+28.3% YoY
- LTMMar 2026
- $9.79M+21.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +0.3% | -100.0% | -100.3 pp |
| 1 year | +28.3% | -100.0% | -128.3 pp |
| 3-year CAGR | +16.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 9.78M USD
- Year-over-year change
- +28.3%
- 4-year CAGR
- +19.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.78M | +28.3% |
| FY2024 | 2024-12-31 | 7.62M | -6.5% |
| FY2023 | 2023-12-31 | 8.16M | +32.4% |
| FY2022 | 2022-12-31 | 6.16M | +26.2% |
| FY2021 | 2021-12-31 | 4.88M | — |
Selling, General & Admin vs competitors
How DMAC compares with its peers on the latest reported figures
- DMAC's LTM Mar 2026 selling, general & admin of $9.79M is the lowest of the 7 companies compared; the peer median is $41.3M.
- Its year-over-year change of +21.7% is the 5th highest of 7, against a peer median of +32.8%.
- Over three fiscal years its annual growth of +16.7% compares with a peer median of +8.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $139.03M | +19.2% | +2.4% | 3857.6% | |
| LTM Mar 2026 | $113.07M | +41.5% | -8.1% | 48.7% | |
| LTM Mar 2026 | $43.56M | -24.4% | -10.0% | 4900.3% | |
| LTM Mar 2026 | $39.04M | +38.9% | +14.7% | 195.2% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $28.7M | +27.8% | +43.3% | 278.2% |
| LTM Mar 2026 | $21.4M | +37.8% | +45.9% | — | |
| LTM Mar 2026 | $9.79M | +21.7% | +16.7% | — | |
| Peer median (excluding DMAC) | $41.3M | +32.8% | +8.5% | 278.2% | |
Competitors are the stored peer set for DMAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 8.77M | 7.84M | 13.11M | 19.06M | 24.61M |
| Selling, General & Admin | 4.88M | 6.16M | 8.16M | 7.62M | 9.78M |
| Operating Expenses | 13.65M | 14M | 21.27M | 26.68M | 34.4M |
| Depreciation & Amortization | 24K | 25K | 30K | 39K | 43K |
| EBITDA | (13.54M) | (13.62M) | (19.31M) | (24.38M) | (32.7M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (13.65M) | (14M) | (21.27M) | (26.68M) | (34.4M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 2.3M | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 82K | 353K | 1.93M | 2.27M | 1.66M |
| Income Before Tax | (13.56M) | (13.65M) | (19.34M) | (24.41M) | (32.74M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 28K | 28K | 43K | 30K | 28K |
| Net Income | (13.59M) | (13.68M) | (19.38M) | (24.44M) | (32.77M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| EPS (Diluted) | (0.65) | (0.52) | (0.60) | (0.60) | (0.70) |
| Weighted Avg Shares | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
| Weighted Avg Shares (Diluted) | 20.77M | 26.44M | 32.57M | 40.4M | 46.98M |
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
Intrinsic Alpha fair value
Locked
Current Price
$8.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.